Chemomab Reports on Two Scientific Presentations that Support the Potential Therapeutic Utility of CM-101 in Systemic Sclerosis
- Monday, March 14, 2022, 7:13
- PR Newswire
- Add a comment
—Translational Study Data Presented at 7th Systemic Sclerosis World Congress Confirms CCL24 is Elevated in Diffuse Cutaneous Systemic Sclerosis Patients; High CCL24 Serum Levels in Patients were Correlated with Greater Disease Activity and Worse Prognosis— —Chemomab Also Presented Data…
About the Author
admin has written 21803 stories on this site.